Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
- Registration Number
- NCT06045195
- Lead Sponsor
- University of Cologne
- Brief Summary
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- age 18-60
- advanced stage classical Hodgkin Lymphoma
- no previous treatment for cHL
Main
Exclusion Criteria
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
- Chemotherapy or radiotherapy in medical history
- Prior or concurrent disease that prevents treatment according to protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Treatment Pembrolizumab Pembrolizumab + BrECADD
- Primary Outcome Measures
Name Time Method progression free survival 1 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pembrolizumab's efficacy in advanced classical Hodgkin Lymphoma (NCT06045195)?
How does pembrolizumab combined with P-BrECADD compare to standard ABVD in first-line Hodgkin Lymphoma treatment?
Which biomarkers correlate with improved progression-free survival in pembrolizumab-based regimens for Hodgkin Lymphoma?
What immune-related adverse events are associated with pembrolizumab in combination with chemo-immunotherapy for Hodgkin Lymphoma?
How do pembrolizumab and other PD-1 inhibitors like nivolumab perform in first-line advanced Hodgkin Lymphoma trials?
Trial Locations
- Locations (1)
1st Department of Medicine, Cologne University Hospital
🇩🇪Cologne, Germany
1st Department of Medicine, Cologne University Hospital🇩🇪Cologne, Germany